Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.29
NVSEF's Cash to Debt is ranked lower than
82% of the 697 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. NVSEF: 0.29 )
Ranked among companies with meaningful Cash to Debt only.
NVSEF' s 10-Year Cash to Debt Range
Min: 0.2  Med: 1.24 Max: N/A
Current: 0.29
Equity to Asset 0.57
NVSEF's Equity to Asset is ranked lower than
58% of the 559 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. NVSEF: 0.57 )
Ranked among companies with meaningful Equity to Asset only.
NVSEF' s 10-Year Equity to Asset Range
Min: 0.51  Med: 0.59 Max: 0.65
Current: 0.57
0.51
0.65
Interest Coverage 15.75
NVSEF's Interest Coverage is ranked lower than
76% of the 372 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 933.44 vs. NVSEF: 15.75 )
Ranked among companies with meaningful Interest Coverage only.
NVSEF' s 10-Year Interest Coverage Range
Min: 13.56  Med: 18.99 Max: 30.91
Current: 15.75
13.56
30.91
F-Score: 5
Z-Score: 2.96
M-Score: -2.33
WACC vs ROIC
8.88%
11.63%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 20.91
NVSEF's Operating margin (%) is ranked higher than
83% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.76 vs. NVSEF: 20.91 )
Ranked among companies with meaningful Operating margin (%) only.
NVSEF' s 10-Year Operating margin (%) Range
Min: 17.81  Med: 21.87 Max: 24.34
Current: 20.91
17.81
24.34
Net-margin (%) 39.05
NVSEF's Net-margin (%) is ranked higher than
96% of the 657 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.85 vs. NVSEF: 39.05 )
Ranked among companies with meaningful Net-margin (%) only.
NVSEF' s 10-Year Net-margin (%) Range
Min: 15.35  Med: 19.24 Max: 31.38
Current: 39.05
15.35
31.38
ROE (%) 29.05
NVSEF's ROE (%) is ranked higher than
90% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.03 vs. NVSEF: 29.05 )
Ranked among companies with meaningful ROE (%) only.
NVSEF' s 10-Year ROE (%) Range
Min: 12.6  Med: 16.53 Max: 25.73
Current: 29.05
12.6
25.73
ROA (%) 16.39
NVSEF's ROA (%) is ranked higher than
88% of the 702 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.05 vs. NVSEF: 16.39 )
Ranked among companies with meaningful ROA (%) only.
NVSEF' s 10-Year ROA (%) Range
Min: 7.21  Med: 10.35 Max: 16.18
Current: 16.39
7.21
16.18
ROC (Joel Greenblatt) (%) 63.37
NVSEF's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.97 vs. NVSEF: 63.37 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVSEF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 43.76  Med: 64.13 Max: 90.24
Current: 63.37
43.76
90.24
Revenue Growth (3Y)(%) -2.00
NVSEF's Revenue Growth (3Y)(%) is ranked lower than
73% of the 541 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. NVSEF: -2.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVSEF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -3.9  Med: 4.80 Max: 73.5
Current: -2
-3.9
73.5
EBITDA Growth (3Y)(%) 5.40
NVSEF's EBITDA Growth (3Y)(%) is ranked lower than
52% of the 482 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.40 vs. NVSEF: 5.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVSEF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -7  Med: 2.00 Max: 82.8
Current: 5.4
-7
82.8
EPS Growth (3Y)(%) 6.00
NVSEF's EPS Growth (3Y)(%) is ranked higher than
51% of the 450 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. NVSEF: 6.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVSEF' s 10-Year EPS Growth (3Y)(%) Range
Min: -7.2  Med: 4.80 Max: 82.2
Current: 6
-7.2
82.2
» NVSEF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with NVSEF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 11.70
NVSEF's P/E(ttm) is ranked higher than
90% of the 470 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.70 vs. NVSEF: 11.70 )
Ranked among companies with meaningful P/E(ttm) only.
NVSEF' s 10-Year P/E(ttm) Range
Min: 7.87  Med: 16.86 Max: 25.64
Current: 11.7
7.87
25.64
Forward P/E 18.05
NVSEF's Forward P/E is ranked higher than
65% of the 232 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.98 vs. NVSEF: 18.05 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 22.90
NVSEF's PE(NRI) is ranked higher than
66% of the 471 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.70 vs. NVSEF: 22.90 )
Ranked among companies with meaningful PE(NRI) only.
NVSEF' s 10-Year PE(NRI) Range
Min: 10.63  Med: 17.83 Max: 25.03
Current: 22.9
10.63
25.03
P/B 3.04
NVSEF's P/B is ranked higher than
55% of the 671 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.39 vs. NVSEF: 3.04 )
Ranked among companies with meaningful P/B only.
NVSEF' s 10-Year P/B Range
Min: 1.69  Med: 2.52 Max: 4.14
Current: 3.04
1.69
4.14
P/S 4.55
NVSEF's P/S is ranked lower than
62% of the 647 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.27 vs. NVSEF: 4.55 )
Ranked among companies with meaningful P/S only.
NVSEF' s 10-Year P/S Range
Min: 1.89  Med: 3.15 Max: 4.96
Current: 4.55
1.89
4.96
PFCF 22.26
NVSEF's PFCF is ranked higher than
76% of the 276 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.86 vs. NVSEF: 22.26 )
Ranked among companies with meaningful PFCF only.
NVSEF' s 10-Year PFCF Range
Min: 7.03  Med: 17.16 Max: 26.64
Current: 22.26
7.03
26.64
POCF 16.83
NVSEF's POCF is ranked higher than
72% of the 385 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.88 vs. NVSEF: 16.83 )
Ranked among companies with meaningful POCF only.
NVSEF' s 10-Year POCF Range
Min: 5.75  Med: 13.04 Max: 19.28
Current: 16.83
5.75
19.28
EV-to-EBIT 19.68
NVSEF's EV-to-EBIT is ranked higher than
59% of the 482 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.80 vs. NVSEF: 19.68 )
Ranked among companies with meaningful EV-to-EBIT only.
NVSEF' s 10-Year EV-to-EBIT Range
Min: 8.9  Med: 16.20 Max: 25.4
Current: 19.68
8.9
25.4
Shiller P/E 20.10
NVSEF's Shiller P/E is ranked higher than
77% of the 311 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 38.44 vs. NVSEF: 20.10 )
Ranked among companies with meaningful Shiller P/E only.
NVSEF' s 10-Year Shiller P/E Range
Min: 9.24  Med: 14.48 Max: 24.94
Current: 20.1
9.24
24.94
Current Ratio 0.88
NVSEF's Current Ratio is ranked lower than
92% of the 605 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. NVSEF: 0.88 )
Ranked among companies with meaningful Current Ratio only.
NVSEF' s 10-Year Current Ratio Range
Min: 0.88  Med: 1.45 Max: 2.83
Current: 0.88
0.88
2.83
Quick Ratio 0.67
NVSEF's Quick Ratio is ranked lower than
89% of the 604 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. NVSEF: 0.67 )
Ranked among companies with meaningful Quick Ratio only.
NVSEF' s 10-Year Quick Ratio Range
Min: 0.66  Med: 1.17 Max: 2.48
Current: 0.67
0.66
2.48
Days Inventory 140.32
NVSEF's Days Inventory is ranked lower than
64% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 113.04 vs. NVSEF: 140.32 )
Ranked among companies with meaningful Days Inventory only.
NVSEF' s 10-Year Days Inventory Range
Min: 117.86  Med: 174.34 Max: 297.21
Current: 140.32
117.86
297.21
Days Sales Outstanding 62.95
NVSEF's Days Sales Outstanding is ranked higher than
58% of the 592 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.21 vs. NVSEF: 62.95 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVSEF' s 10-Year Days Sales Outstanding Range
Min: 53.85  Med: 64.06 Max: 79.16
Current: 62.95
53.85
79.16

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.73
NVSEF's Dividend Yield is ranked higher than
92% of the 636 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.19 vs. NVSEF: 2.73 )
Ranked among companies with meaningful Dividend Yield only.
NVSEF' s 10-Year Dividend Yield Range
Min: 1.47  Med: 3.10 Max: 5.11
Current: 2.73
1.47
5.11
Dividend Payout 0.64
NVSEF's Dividend Payout is ranked higher than
81% of the 394 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. NVSEF: 0.64 )
Ranked among companies with meaningful Dividend Payout only.
NVSEF' s 10-Year Dividend Payout Range
Min: 0.51  Med: 1.53 Max: 2.73
Current: 0.64
0.51
2.73
Dividend growth (3y) 6.80
NVSEF's Dividend growth (3y) is ranked higher than
50% of the 253 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. NVSEF: 6.80 )
Ranked among companies with meaningful Dividend growth (3y) only.
NVSEF' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 7.45 Max: 18.5
Current: 6.8
0
18.5
Yield on cost (5-Year) 3.97
NVSEF's Yield on cost (5-Year) is ranked higher than
93% of the 636 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.55 vs. NVSEF: 3.97 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NVSEF' s 10-Year Yield on cost (5-Year) Range
Min: 2.14  Med: 4.53 Max: 7.44
Current: 3.97
2.14
7.44
Share Buyback Rate -0.20
NVSEF's Share Buyback Rate is ranked higher than
70% of the 431 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.30 vs. NVSEF: -0.20 )
Ranked among companies with meaningful Share Buyback Rate only.
NVSEF' s 10-Year Share Buyback Rate Range
Min: 41.9  Med: 0.90 Max: -2.5
Current: -0.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 25.70
NVSEF's Price/Tangible Book is ranked lower than
96% of the 620 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.04 vs. NVSEF: 25.70 )
Ranked among companies with meaningful Price/Tangible Book only.
NVSEF' s 10-Year Price/Tangible Book Range
Min: 0.16  Med: 4.13 Max: 94.26
Current: 25.7
0.16
94.26
Price/Projected FCF 1.45
NVSEF's Price/Projected FCF is ranked higher than
80% of the 319 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.94 vs. NVSEF: 1.45 )
Ranked among companies with meaningful Price/Projected FCF only.
NVSEF' s 10-Year Price/Projected FCF Range
Min: 0.11  Med: 0.90 Max: 1.89
Current: 1.45
0.11
1.89
Price/Median PS Value 1.44
NVSEF's Price/Median PS Value is ranked lower than
60% of the 598 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.30 vs. NVSEF: 1.44 )
Ranked among companies with meaningful Price/Median PS Value only.
NVSEF' s 10-Year Price/Median PS Value Range
Min: 0.66  Med: 1.16 Max: 3.21
Current: 1.44
0.66
3.21
Price/Graham Number 5.10
NVSEF's Price/Graham Number is ranked lower than
79% of the 359 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.57 vs. NVSEF: 5.10 )
Ranked among companies with meaningful Price/Graham Number only.
NVSEF' s 10-Year Price/Graham Number Range
Min: 0.07  Med: 1.86 Max: 76.65
Current: 5.1
0.07
76.65
Earnings Yield (Greenblatt) (%) 5.10
NVSEF's Earnings Yield (Greenblatt) (%) is ranked higher than
71% of the 683 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. NVSEF: 5.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVSEF' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 3.9  Med: 6.20 Max: 11.3
Current: 5.1
3.9
11.3
Forward Rate of Return (Yacktman) (%) 1.35
NVSEF's Forward Rate of Return (Yacktman) (%) is ranked lower than
60% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.89 vs. NVSEF: 1.35 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NVSEF' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 0.6  Med: 14.40 Max: 79.5
Current: 1.35
0.6
79.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:0HKE.UK, NOVN.Switzerland, NVS.USA, NOT.Germany, NOTA.Germany, NVS.Argentina, NVS N.Mexico, NOVNEE.Switzerland,
Novartis AG was incorporated on February 29, 1996 under the Swiss laws. On December 20, 1996, its predecessor companies, Ciba-Geigy AG and Sandoz AG, merged into this new entity, creating Novartis. The Company is engaged in the research, development, manufacturing and marketing of healthcare and pharmaceuticals products. The Company's portfolio includes innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The Company's wholly-owned businesses are organized into six global operating divisions, and they report teir results in the following five segments; Pharmaceuticals: Innovative patent-protected prescription medicines, Alcon: Surgical, ophthalmic pharmaceutical and vision care products, Sandoz: Generic pharmaceuticals, Vaccines and Diagnostics: Preventive human vaccines and blood testing diagnostics, Consumer Health: OTC (over-the-counter medicines) and Animal Health. The Pharmaceuticals division researches, develops, manufactures, distributes and sells patented prescription medicines and is organized in the following business franchises: Primary Care, consisting of Primary Care medicines and Established Medicines; and Specialty Care, consisting of Ophthalmology, Neuroscience, Integrated Hospital Care, and Critical Care medicines. The manufacture of the products is complex and heavily regulated by governmental health authorities, which means that supply is never guaranteed. If the Company or its third party suppliers fail to comply with applicable regulations then there could be a product recall or other shutdown or disruption of its production activities. The Company is subject to the laws of Switzerland, in particular Swiss company and securities laws, and to the securities laws of the United States as applicable to foreign private issuers of securities.
» More Articles for NVSEF

Headlines

Articles On GuruFocus.com
Bill Frels' Stocks With Highest-Growing Yields Jun 26 2015 
Bill Frels' Stocks With Growing Yields Jun 27 2015 
Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The Cost Tells A Different Story Jun 22 2015 
Follow Bill Ackman in Valeant Pharmaceuticals Jun 19 2015 
Billionaire George Soros Ups Two Stakes in First Quarter Jun 16 2015 
Will GlaxoSmithKline Cut Its 6% Dividend? Jun 03 2015 
Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 
8 Top Healthcare Stocks to Watch May 13 2015 
Amgen Reports An Upbeat Q1 Earnings Apr 23 2015 
Top Weighted Stocks in Tweedy Browne Global Value Fund's Portfolio Apr 22 2015 

More From Other Websites
US seeks $3.3 bn corruption fine from Novartis Jul 01 2015
U.S. Seeks $3.3 Billion From Novartis in Drug Kickback Suit Jul 01 2015
US seeks $3.3 bn corruption fine from Novartis Jun 30 2015
Novartis (NVS) Stock Declines as U.S. Seeks $3.35 Billion Fine Jun 30 2015
How Much?! Feds Wants Novartis to pay $3.35B For Kickback Schemes Jun 30 2015
U.S. seeks up to $3.35 billion in Novartis kickback lawsuit Jun 30 2015
Roche 'High Efficacy' MS Drug Succeeds In Trials Jun 30 2015
Novartis' Cosentyx Positive in Psoriatic Arthritis Study - Analyst Blog Jun 29 2015
Novartis to Pay at Least $200 Million for Chronic Pain Medicine Jun 29 2015
Switzerland's Novartis buys US biotech firm Spinifex Jun 29 2015
Switzerland's Novartis buys US biotech firm Spinifex Jun 29 2015
Novartis buys Spinifex for $US200m plus Jun 29 2015
Novartis buys pain drug firm Spinifex for $200 mln upfront Jun 29 2015
New data fuel hopes for broad use of Novartis psoriasis drug Jun 28 2015
Europe gives green light to new Novartis, Alexion drugs Jun 26 2015
Cancer Therapy Boosts Appeal of Juno, Kite as Targets: Real M&A Jun 23 2015
GSK Vaccinates Pfizer to Gain Novartis - Video Blog Jun 23 2015
Pfizer to buy two vaccines from Glaxo Jun 22 2015
GSK sells two meningitis drugs to Pfizer for £82m Jun 22 2015
Medical researchers use the cloud to do what they couldn’t before Jun 19 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK